 Philip Palade
Concepts (191)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Calcium Channels, L-Type | 8 | 2010 | 67 | 1.490 |
Why?
| | Myocardium | 5 | 2013 | 438 | 0.650 |
Why?
| | Angiotensin II | 2 | 2010 | 157 | 0.620 |
Why?
| | Endothelium, Vascular | 2 | 2010 | 254 | 0.600 |
Why?
| | Promoter Regions, Genetic | 4 | 2005 | 475 | 0.580 |
Why?
| | Calcium | 7 | 2013 | 400 | 0.550 |
Why?
| | Myocytes, Cardiac | 5 | 2013 | 125 | 0.520 |
Why?
| | Exons | 4 | 2006 | 95 | 0.430 |
Why?
| | Rats | 13 | 2020 | 3299 | 0.380 |
Why?
| | Sulfoxides | 2 | 2021 | 19 | 0.380 |
Why?
| | Isothiocyanates | 2 | 2021 | 17 | 0.380 |
Why?
| | NF-E2-Related Factor 2 | 2 | 2021 | 41 | 0.370 |
Why?
| | Heart Ventricles | 5 | 2013 | 251 | 0.350 |
Why?
| | Hydrogen Peroxide | 1 | 2010 | 115 | 0.350 |
Why?
| | Muscle, Smooth | 3 | 2005 | 64 | 0.340 |
Why?
| | Vasoconstrictor Agents | 1 | 2010 | 84 | 0.340 |
Why?
| | Animals | 22 | 2024 | 13246 | 0.330 |
Why?
| | Rats, Sprague-Dawley | 7 | 2020 | 1586 | 0.300 |
Why?
| | Gene Expression Regulation | 4 | 2021 | 979 | 0.280 |
Why?
| | Protein Isoforms | 3 | 2007 | 119 | 0.280 |
Why?
| | Kv1.2 Potassium Channel | 1 | 2006 | 2 | 0.280 |
Why?
| | NADP | 1 | 2006 | 22 | 0.280 |
Why?
| | Second Messenger Systems | 1 | 2006 | 14 | 0.280 |
Why?
| | Myometrium | 1 | 2006 | 14 | 0.280 |
Why?
| | Alternative Splicing | 1 | 2006 | 56 | 0.270 |
Why?
| | Blood Vessels | 1 | 2006 | 71 | 0.260 |
Why?
| | Myocardial Contraction | 3 | 2013 | 107 | 0.250 |
Why?
| | Muscle Contraction | 2 | 2020 | 106 | 0.250 |
Why?
| | Calcium Signaling | 3 | 2013 | 56 | 0.240 |
Why?
| | Patch-Clamp Techniques | 4 | 2012 | 124 | 0.230 |
Why?
| | Oxidative Stress | 3 | 2021 | 771 | 0.210 |
Why?
| | Calcium Channel Agonists | 1 | 2002 | 3 | 0.210 |
Why?
| | GTPase-Activating Proteins | 1 | 2021 | 23 | 0.200 |
Why?
| | Pyrroles | 1 | 2002 | 69 | 0.200 |
Why?
| | Skin Aging | 1 | 2021 | 12 | 0.190 |
Why?
| | Cells, Cultured | 6 | 2020 | 1581 | 0.190 |
Why?
| | KATP Channels | 1 | 2020 | 6 | 0.190 |
Why?
| | Lymphatic Vessels | 1 | 2020 | 48 | 0.180 |
Why?
| | Edema | 1 | 2020 | 69 | 0.170 |
Why?
| | Molecular Sequence Data | 4 | 2005 | 793 | 0.160 |
Why?
| | Cardiovascular Diseases | 1 | 2024 | 443 | 0.160 |
Why?
| | Apoptosis | 1 | 2024 | 1112 | 0.160 |
Why?
| | Male | 13 | 2021 | 25399 | 0.160 |
Why?
| | Mice | 8 | 2021 | 5759 | 0.160 |
Why?
| | Mitochondria | 1 | 2021 | 404 | 0.150 |
Why?
| | Base Sequence | 3 | 2005 | 644 | 0.150 |
Why?
| | Calcium Channel Blockers | 3 | 2009 | 63 | 0.150 |
Why?
| | Alzheimer Disease | 1 | 2021 | 317 | 0.150 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2010 | 129 | 0.150 |
Why?
| | Models, Biological | 3 | 2021 | 723 | 0.130 |
Why?
| | Receptors, LDL | 2 | 2014 | 66 | 0.130 |
Why?
| | Electrophysiological Phenomena | 1 | 2013 | 18 | 0.110 |
Why?
| | Signal Transduction | 4 | 2024 | 1622 | 0.110 |
Why?
| | Sarcoplasmic Reticulum | 3 | 2010 | 21 | 0.110 |
Why?
| | Lipoproteins, LDL | 1 | 2014 | 170 | 0.100 |
Why?
| | Muscle, Skeletal | 2 | 2008 | 765 | 0.100 |
Why?
| | Myofibrils | 2 | 2012 | 19 | 0.100 |
Why?
| | Diet, High-Fat | 1 | 2014 | 220 | 0.100 |
Why?
| | Kidney Diseases | 1 | 2014 | 214 | 0.100 |
Why?
| | Calcium Channels | 3 | 2010 | 46 | 0.100 |
Why?
| | Action Potentials | 2 | 2020 | 132 | 0.090 |
Why?
| | Mesenteric Arteries | 1 | 2010 | 45 | 0.090 |
Why?
| | Cell Membrane | 3 | 2010 | 251 | 0.090 |
Why?
| | Amlodipine | 1 | 2009 | 14 | 0.090 |
Why?
| | Fluorobenzenes | 1 | 2009 | 21 | 0.090 |
Why?
| | Cardiomegaly | 1 | 2009 | 36 | 0.080 |
Why?
| | Antioxidants | 2 | 2021 | 241 | 0.080 |
Why?
| | Hypercholesterolemia | 1 | 2009 | 36 | 0.080 |
Why?
| | Myocardial Infarction | 1 | 2013 | 396 | 0.080 |
Why?
| | MicroRNAs | 1 | 2013 | 355 | 0.080 |
Why?
| | Membrane Glycoproteins | 1 | 2010 | 246 | 0.080 |
Why?
| | Mesenteric Artery, Superior | 1 | 2008 | 10 | 0.080 |
Why?
| | Tissue Culture Techniques | 1 | 2008 | 40 | 0.080 |
Why?
| | Extracellular Fluid | 1 | 2008 | 14 | 0.080 |
Why?
| | Muscle Fatigue | 1 | 2008 | 10 | 0.080 |
Why?
| | Up-Regulation | 1 | 2010 | 453 | 0.080 |
Why?
| | Sulfonamides | 1 | 2009 | 128 | 0.080 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 138 | 0.080 |
Why?
| | Pyrimidines | 1 | 2009 | 193 | 0.080 |
Why?
| | Rats, Wistar | 2 | 2007 | 222 | 0.080 |
Why?
| | Sodium | 2 | 2012 | 93 | 0.080 |
Why?
| | Cytosol | 2 | 2010 | 82 | 0.070 |
Why?
| | Muscle Strength | 1 | 2008 | 125 | 0.070 |
Why?
| | Molecular Motor Proteins | 1 | 2007 | 9 | 0.070 |
Why?
| | Isometric Contraction | 1 | 2007 | 21 | 0.070 |
Why?
| | ADP-ribosyl Cyclase | 1 | 2006 | 5 | 0.070 |
Why?
| | Gene Expression | 2 | 2009 | 609 | 0.070 |
Why?
| | Rats, Inbred SHR | 1 | 2006 | 35 | 0.070 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 595 | 0.070 |
Why?
| | Organ Specificity | 1 | 2006 | 108 | 0.070 |
Why?
| | Membrane Potentials | 2 | 2006 | 117 | 0.070 |
Why?
| | Sequence Homology, Amino Acid | 2 | 2003 | 144 | 0.070 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2005 | 17 | 0.070 |
Why?
| | Transcription Factor RelA | 1 | 2005 | 30 | 0.070 |
Why?
| | Ryanodine Receptor Calcium Release Channel | 3 | 2013 | 13 | 0.060 |
Why?
| | Aorta | 1 | 2006 | 162 | 0.060 |
Why?
| | Colon | 1 | 2005 | 94 | 0.060 |
Why?
| | PC12 Cells | 1 | 2005 | 24 | 0.060 |
Why?
| | RNA, Messenger | 3 | 2021 | 1108 | 0.060 |
Why?
| | Diaphragm | 1 | 2005 | 31 | 0.060 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2020 | 86 | 0.060 |
Why?
| | Humans | 8 | 2024 | 50208 | 0.060 |
Why?
| | Sequence Analysis, DNA | 1 | 2005 | 238 | 0.060 |
Why?
| | Muscle Proteins | 1 | 2007 | 312 | 0.060 |
Why?
| | DNA Probes | 1 | 2003 | 30 | 0.050 |
Why?
| | Sphingolipids | 1 | 2002 | 15 | 0.050 |
Why?
| | Fibrosis | 2 | 2014 | 180 | 0.050 |
Why?
| | 5' Untranslated Regions | 1 | 2002 | 31 | 0.050 |
Why?
| | Calmodulin | 2 | 2013 | 10 | 0.050 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 2 | 2013 | 13 | 0.050 |
Why?
| | Nifedipine | 1 | 2002 | 25 | 0.050 |
Why?
| | Extracellular Space | 1 | 2002 | 38 | 0.050 |
Why?
| | Mitochondrial Dynamics | 1 | 2021 | 18 | 0.050 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2021 | 33 | 0.050 |
Why?
| | Transfection | 1 | 2002 | 355 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2021 | 1458 | 0.050 |
Why?
| | Synapses | 1 | 2021 | 86 | 0.050 |
Why?
| | Calcineurin | 2 | 2013 | 71 | 0.050 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 586 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2021 | 89 | 0.050 |
Why?
| | Cromakalim | 1 | 2020 | 4 | 0.050 |
Why?
| | Minoxidil | 1 | 2020 | 5 | 0.050 |
Why?
| | Diazoxide | 1 | 2020 | 6 | 0.050 |
Why?
| | Potassium | 1 | 2020 | 56 | 0.050 |
Why?
| | Kinetics | 2 | 2013 | 631 | 0.050 |
Why?
| | Hypertension | 1 | 2006 | 537 | 0.050 |
Why?
| | Behavior, Animal | 1 | 2021 | 180 | 0.050 |
Why?
| | Heart | 1 | 2002 | 331 | 0.040 |
Why?
| | Sarcopenia | 1 | 2020 | 84 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2021 | 408 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2014 | 846 | 0.040 |
Why?
| | Ion Channel Gating | 2 | 2010 | 39 | 0.040 |
Why?
| | Dietary Supplements | 1 | 2021 | 434 | 0.040 |
Why?
| | Inflammation | 1 | 2021 | 604 | 0.040 |
Why?
| | Brain | 1 | 2005 | 1328 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 1819 | 0.030 |
Why?
| | Blood Pressure | 2 | 2009 | 524 | 0.030 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2013 | 8 | 0.030 |
Why?
| | Sarcomeres | 1 | 2013 | 4 | 0.030 |
Why?
| | Dihydropyridines | 1 | 2013 | 8 | 0.030 |
Why?
| | Cyclic GMP | 1 | 2013 | 20 | 0.030 |
Why?
| | Lipid Peroxidation | 1 | 2014 | 100 | 0.030 |
Why?
| | Intracellular Space | 1 | 2013 | 25 | 0.030 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2014 | 60 | 0.030 |
Why?
| | Aldehydes | 1 | 2014 | 83 | 0.030 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2013 | 42 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2014 | 155 | 0.030 |
Why?
| | Cyclic AMP | 1 | 2013 | 91 | 0.030 |
Why?
| | Collagen | 1 | 2014 | 207 | 0.030 |
Why?
| | NF-kappa B | 1 | 2014 | 315 | 0.030 |
Why?
| | Models, Animal | 1 | 2012 | 232 | 0.020 |
Why?
| | Temperature | 1 | 2012 | 168 | 0.020 |
Why?
| | Fibroblasts | 1 | 2014 | 351 | 0.020 |
Why?
| | Thapsigargin | 1 | 2010 | 10 | 0.020 |
Why?
| | Ion Transport | 1 | 2010 | 16 | 0.020 |
Why?
| | Cell Compartmentation | 1 | 2010 | 15 | 0.020 |
Why?
| | Caffeine | 1 | 2010 | 66 | 0.020 |
Why?
| | Cholesterol, Dietary | 1 | 2009 | 19 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2014 | 1013 | 0.020 |
Why?
| | Lipids | 1 | 2009 | 148 | 0.020 |
Why?
| | Protein Binding | 1 | 2010 | 665 | 0.020 |
Why?
| | Purinergic P2 Receptor Antagonists | 1 | 2008 | 4 | 0.020 |
Why?
| | Elapid Venoms | 1 | 2008 | 3 | 0.020 |
Why?
| | Calcimycin | 1 | 2008 | 6 | 0.020 |
Why?
| | Ionophores | 1 | 2008 | 6 | 0.020 |
Why?
| | Sodium-Calcium Exchanger | 1 | 2008 | 8 | 0.020 |
Why?
| | Thiourea | 1 | 2008 | 9 | 0.020 |
Why?
| | Suramin | 1 | 2008 | 12 | 0.020 |
Why?
| | Pyridoxal Phosphate | 1 | 2008 | 10 | 0.020 |
Why?
| | Triazines | 1 | 2008 | 24 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2009 | 381 | 0.020 |
Why?
| | Electric Stimulation | 1 | 2008 | 118 | 0.020 |
Why?
| | Receptors, Purinergic P2 | 1 | 2008 | 39 | 0.020 |
Why?
| | Gadolinium | 1 | 2008 | 43 | 0.020 |
Why?
| | Body Weight | 1 | 2009 | 512 | 0.020 |
Why?
| | Genetic Complementation Test | 1 | 2005 | 47 | 0.020 |
Why?
| | Female | 1 | 2006 | 26635 | 0.020 |
Why?
| | Protein Conformation | 1 | 2006 | 168 | 0.020 |
Why?
| | Antihypertensive Agents | 1 | 2006 | 121 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2005 | 369 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2002 | 48 | 0.010 |
Why?
| | Protein Structure, Quaternary | 1 | 2002 | 26 | 0.010 |
Why?
| | Dimerization | 1 | 2002 | 50 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 2002 | 25 | 0.010 |
Why?
| | Microtubules | 1 | 2002 | 45 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 2002 | 82 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2002 | 135 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 2922 | 0.010 |
Why?
| | Animals, Newborn | 1 | 2002 | 368 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2002 | 978 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2009 | 5155 | 0.010 |
Why?
|
|
Palade's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|